Printer-friendly versionPrinter-friendly version

Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study/

While new direct-acting antivirals introduced are now effective enough to cure more than 90% of hepatitis C cases, it is not known whether there are suitable policies to promote access to treatment in European countries. The Hep-CORE study collected information on viral hepatitis policy issues from patient groups belonging to the European Liver Patients Association (ELPA) and offers insight into this situation.

Tags: